Validation of the partin nomogram for prostate cancer in a national sample.
暂无分享,去创建一个
Alan W Partin | Cary P Gross | Danil V Makarov | James B Yu | C. Gross | A. Partin | R. Peschel | D. Makarov | James B. Yu | Richa Sharma | Richard E Peschel | Richa Sharma
[1] Tumor thickness predicts a five-year survival equally as well as more complex prognostic model , 2000 .
[2] E. Klein,et al. Limited pelvic lymph node dissection does not improve biochemical relapse-free survival at 10 years after radical prostatectomy in patients with low-risk prostate cancer. , 2008, Urology.
[3] R. Riffenburgh,et al. Grading inaccuracies in diagnostic biopsies revealing prostatic adenocarcinoma: implications for definitive radiation therapy. , 1995, International journal of radiation oncology, biology, physics.
[4] A. Haese*,et al. Percent free prostate‐specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower , 2008, Cancer.
[5] A. Partin,et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. , 2001, The Urologic clinics of North America.
[6] James M Henning,et al. How well does the Partin nomogram predict pathological stage after radical prostatectomy in a community based population? Results of the cancer of the prostate strategic urological research endeavor. , 2002, The Journal of urology.
[7] A W Partin,et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. , 2002, Urology.
[8] Y. Ben-Shlomo,et al. Investigating Black‐White differences in prostate cancer prognosis: A systematic review and meta‐analysis , 2008, International journal of cancer.
[9] M. Terris,et al. The effect of race/ethnicity on the accuracy of the 2001 Partin Tables for predicting pathologic stage of localized prostate cancer. , 2008, Urology.
[10] A W Partin,et al. Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. , 2000, The Journal of urology.
[11] L. Capps. Unequal Treatment: Confronting Racial and Ethnic Disparities in Healthcare , 2003 .
[12] D. Chan,et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. , 1993, The Journal of urology.
[13] A. D'Amico,et al. Critical analysis of the ability of the endorectal coil magnetic resonance imaging scan to predict pathologic stage, margin status, and postoperative prostate-specific antigen failure in patients with clinically organ-confined prostate cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] P. Walsh,et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. , 2003, The Journal of urology.
[15] Pierre I Karakiewicz,et al. Comparison of accuracy between the Partin tables of 1997 and 2001 to predict final pathological stage in clinically localized prostate cancer. , 2004, The Journal of urology.
[16] A. Haese*,et al. Partin Tables cannot accurately predict the pathological stage at radical prostatectomy. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[17] A. D'Amico,et al. PSA velocity is associated with gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness. , 2008, Urology.
[18] Haiqun Lin,et al. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma. , 2005, The Journal of urology.
[19] Umberto Capitanio,et al. External validation of the updated Partin tables in a cohort of North American men. , 2008, The Journal of urology.
[20] G. Brier. VERIFICATION OF FORECASTS EXPRESSED IN TERMS OF PROBABILITY , 1950 .
[21] A. Renshaw,et al. Advanced age at diagnosis is an independent predictor of time to death from prostate carcinoma for patients undergoing external beam radiation therapy for clinically localized prostate carcinoma , 2003, Cancer.
[22] Umberto Capitanio,et al. External validation of the updated partin tables in a cohort of French and Italian men. , 2009, International journal of radiation oncology, biology, physics.
[23] E. DeLong,et al. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.
[24] F. Montorsi,et al. Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer , 2006, BJU international.
[25] A W Partin,et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.
[26] Alan W Partin,et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. , 2007, Urology.
[27] P. Walsh,et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. , 1994, JAMA.
[28] J. Moul,et al. Percent tumor involvement and risk of biochemical progression after radical prostatectomy. , 2008, The Journal of urology.